Immune Disease | Viral Safety

GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10%

GAMMAGARD LIQUID 10% is the first 10% IVIG solution treated with a dedicated 3-step process specifically designed for viral inactivation/removal.¹

3 stps of viral removal

GAMMAGARD LIQUID 10% is sourced and processed exclusively from plasma collected at FDA-registered donor sites.¹

Donations are individually screened for HBsAg and for antibodies to HIV-1, HIV-2, and HCV*
Mini-pools of collected plasma are further tested with FDA-approved nucleic acid testing
IgGs are purified from plasma pools with a modified Cohn-Oncley fractionation process, and cation and anion exchange chromatograph

Learn about the steps Baxter is taking to protect GAMMAGARD LIQUID 10% against specific viral agents.

As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated.

GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Please see Important Safety Information and Full Prescribing Information for GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10%

To view PDFs, you will need Adobe® Acrobat® Reader® software.

*EMCV (encephalomyocarditis virus), HAV (hepatitis A virus), MMV (mice minute virus), B19V (human parvovirus B19), HBsAg (hepatitis B surface antigen), HIV (human immunodeficiency virus), HCV (hepatitis C virus)

1. GAMMAGARD LIQUID Immune Globulin Intravenous (Human) 10% [package insert]. Deerfield, IL. Baxter International Inc.; April 2005.

Sign Up Today